Cardio-oncology is a discipline based on early screening,monitoring,and treating chemotherapy-induced cardiotoxicity.There are many chemotherapeutics known for their cardiac toxic effects,including fluoropyrimidines.F...Cardio-oncology is a discipline based on early screening,monitoring,and treating chemotherapy-induced cardiotoxicity.There are many chemotherapeutics known for their cardiac toxic effects,including fluoropyrimidines.Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment.Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms,from angina pectoris to sudden death.This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented,the mechanisms of its occurrence,its diagnosis,and management.展开更多
Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions...Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions,such as liver cirrhosis and hepatocellular carcinoma.Recent years have uncovered an important interplay between the liver and the gut microbiome:the gut-liver axis.Hepatitis B and C infections often cause alterations in the gut microbiota by lowering the levels of‘protective’gut microorganisms and,by doing so,hinder the microbiota ability to boost the immune response.Treatments aimed at restoring the gut microbiota balance may provide a valuable addition to current practice therapies and may help limit the chronic changes observed in the liver of hepatitis B and C patients.This review aims to summarize the current knowledge on the anatofunctional axis between the gut and liver and to highlight the influence that hepatitis B and C viruses have on the microbiota balance,as well as the influence of treatments aimed at restoring the gut microbiota on infected livers and disease progression.展开更多
Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends...Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends on many factors(e.g.,associated comorbidities,age,etc)and may have various clinical and imaging findings,which raises management concerns.Gut microbiota composition is known to influence respiratory disease,and respiratory viral infection can also influence gut microbiota.Gut and lung microbiota and their relationship(gut-lung axis)can act as modulators of inflammation.Modulating the intestinal microbiota,by improving its composition and diversity through nutraceutical agents,can have a positive impact in the prophylaxis/treatment of COVID-19.展开更多
文摘Cardio-oncology is a discipline based on early screening,monitoring,and treating chemotherapy-induced cardiotoxicity.There are many chemotherapeutics known for their cardiac toxic effects,including fluoropyrimidines.Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment.Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms,from angina pectoris to sudden death.This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented,the mechanisms of its occurrence,its diagnosis,and management.
文摘Viral B and C hepatitis are a major current health issue,both diseases having a chronic damaging effect on the liver and its functions.Chronic liver disease can lead to even more severe and life-threatening conditions,such as liver cirrhosis and hepatocellular carcinoma.Recent years have uncovered an important interplay between the liver and the gut microbiome:the gut-liver axis.Hepatitis B and C infections often cause alterations in the gut microbiota by lowering the levels of‘protective’gut microorganisms and,by doing so,hinder the microbiota ability to boost the immune response.Treatments aimed at restoring the gut microbiota balance may provide a valuable addition to current practice therapies and may help limit the chronic changes observed in the liver of hepatitis B and C patients.This review aims to summarize the current knowledge on the anatofunctional axis between the gut and liver and to highlight the influence that hepatitis B and C viruses have on the microbiota balance,as well as the influence of treatments aimed at restoring the gut microbiota on infected livers and disease progression.
文摘Coronavirus disease 2019(COVID-19),caused by a severe acute respiratory syndrome coronavirus 2 infection,has raised serious concerns worldwide over the past 3 years.The severity and clinical course of COVID-19 depends on many factors(e.g.,associated comorbidities,age,etc)and may have various clinical and imaging findings,which raises management concerns.Gut microbiota composition is known to influence respiratory disease,and respiratory viral infection can also influence gut microbiota.Gut and lung microbiota and their relationship(gut-lung axis)can act as modulators of inflammation.Modulating the intestinal microbiota,by improving its composition and diversity through nutraceutical agents,can have a positive impact in the prophylaxis/treatment of COVID-19.
